Hepatic encephalopathy (HE) is a severe complication of chronic liver disease (CLD). Treatments for HE have focused on reducing plasma ammonia levels implicated in HE pathogenesis. The antibiotic rifaximin reduces the production of gut ammonia which is considered to be the main toxin in CLD-induced HE. Rifaximin is commonly used in the treatment of HE and has been shown to reduce the frequency of HE episodes, but the molecular mechanisms behind this effect are unknown. We assessed, in vivo and longitudinally, the effect of rifaximin on brain metabolites in bile duct ligated rats using high-field proton Magnetic Resonance Spectroscopy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords